PortalPublikationenUpregulation of PTTG1 is associated with poor prognosis in p...

Upregulation of PTTG1 is associated with poor prognosis in prostate cancer

Standard

Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. / Fraune, Christoph; Yehorov, Serhiy; Luebke, Andreas M; Steurer, Stefan; Hube-Magg, Claudia; Büscheck, Franziska; Höflmayer, Doris; Tsourlakis, Maria Christina; Clauditz, Till S; Simon, Ronald; Sauter, Guido; Weidemann, Sören; Dum, David; Kind, Simon; Minner, Sarah; Schlomm, Thorsten; Huland, Hartwig; Heinzer, Hans; Graefen, Markus; Burandt, Eike.

in: PATHOL INT, Jahrgang 70, Nr. 7, 07.2020, S. 441-451.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fraune, C, Yehorov, S, Luebke, AM, Steurer, S, Hube-Magg, C, Büscheck, F, Höflmayer, D, Tsourlakis, MC, Clauditz, TS, Simon, R, Sauter, G, Weidemann, S, Dum, D, Kind, S, Minner, S, Schlomm, T, Huland, H, Heinzer, H, Graefen, M & Burandt, E 2020, 'Upregulation of PTTG1 is associated with poor prognosis in prostate cancer', PATHOL INT, Jg. 70, Nr. 7, S. 441-451. https://doi.org/10.1111/pin.12938

APA

Fraune, C., Yehorov, S., Luebke, A. M., Steurer, S., Hube-Magg, C., Büscheck, F., Höflmayer, D., Tsourlakis, M. C., Clauditz, T. S., Simon, R., Sauter, G., Weidemann, S., Dum, D., Kind, S., Minner, S., Schlomm, T., Huland, H., Heinzer, H., Graefen, M., & Burandt, E. (2020). Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. PATHOL INT, 70(7), 441-451. https://doi.org/10.1111/pin.12938

Vancouver

Fraune C, Yehorov S, Luebke AM, Steurer S, Hube-Magg C, Büscheck F et al. Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. PATHOL INT. 2020 Jul;70(7):441-451. https://doi.org/10.1111/pin.12938

Bibtex

@article{4a4b669b28e342d7aded2a4a5522d3b1,
title = "Upregulation of PTTG1 is associated with poor prognosis in prostate cancer",
abstract = "Pituitary tumor-transforming gene 1 (PTTG1) is a regulator of chromosome stability. PTTG1 overexpression had been associated with tumor aggressiveness in several cancer types. To examine its prognostic utility in prostate cancer, a tissue microarray including 12 427 tumors with clinical and molecular data was analyzed by immunohistochemistry. PTTG1 immunostaining was largely absent in normal prostate epithelial cells. In cancers, staining was considered weak in 5.4%, moderate in 5.6% and strong in 0.8%. Strong staining was linked to advanced pT stage, high classical and quantitative Gleason grade, high Ki67-labeling index (all P < 0.0001) and lymph node metastasis (P = 0.0083). The prognostic impact of PTTG1 expression was independent of established preoperative and postoperative prognostic features. Comparison with molecular features revealed that PTTG1 upregulation was associated with nine of 12 common genomic deletions (P < 0.05), p53 alterations and high androgen receptor levels (P < 0.001 each), but was unrelated to the TMPRSS2:ERG fusion status. In conclusion, these data identify PTTG1 as a strong and independent prognostic feature in prostate cancer. PTTG1 measurement, either alone or in combination with other biomarkers might be instrumental for determining prostate cancer aggressiveness.",
author = "Christoph Fraune and Serhiy Yehorov and Luebke, {Andreas M} and Stefan Steurer and Claudia Hube-Magg and Franziska B{\"u}scheck and Doris H{\"o}flmayer and Tsourlakis, {Maria Christina} and Clauditz, {Till S} and Ronald Simon and Guido Sauter and S{\"o}ren Weidemann and David Dum and Simon Kind and Sarah Minner and Thorsten Schlomm and Hartwig Huland and Hans Heinzer and Markus Graefen and Eike Burandt",
note = "{\textcopyright} 2020 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.",
year = "2020",
month = jul,
doi = "10.1111/pin.12938",
language = "English",
volume = "70",
pages = "441--451",
journal = "PATHOL INT",
issn = "1320-5463",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Upregulation of PTTG1 is associated with poor prognosis in prostate cancer

AU - Fraune, Christoph

AU - Yehorov, Serhiy

AU - Luebke, Andreas M

AU - Steurer, Stefan

AU - Hube-Magg, Claudia

AU - Büscheck, Franziska

AU - Höflmayer, Doris

AU - Tsourlakis, Maria Christina

AU - Clauditz, Till S

AU - Simon, Ronald

AU - Sauter, Guido

AU - Weidemann, Sören

AU - Dum, David

AU - Kind, Simon

AU - Minner, Sarah

AU - Schlomm, Thorsten

AU - Huland, Hartwig

AU - Heinzer, Hans

AU - Graefen, Markus

AU - Burandt, Eike

N1 - © 2020 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

PY - 2020/7

Y1 - 2020/7

N2 - Pituitary tumor-transforming gene 1 (PTTG1) is a regulator of chromosome stability. PTTG1 overexpression had been associated with tumor aggressiveness in several cancer types. To examine its prognostic utility in prostate cancer, a tissue microarray including 12 427 tumors with clinical and molecular data was analyzed by immunohistochemistry. PTTG1 immunostaining was largely absent in normal prostate epithelial cells. In cancers, staining was considered weak in 5.4%, moderate in 5.6% and strong in 0.8%. Strong staining was linked to advanced pT stage, high classical and quantitative Gleason grade, high Ki67-labeling index (all P < 0.0001) and lymph node metastasis (P = 0.0083). The prognostic impact of PTTG1 expression was independent of established preoperative and postoperative prognostic features. Comparison with molecular features revealed that PTTG1 upregulation was associated with nine of 12 common genomic deletions (P < 0.05), p53 alterations and high androgen receptor levels (P < 0.001 each), but was unrelated to the TMPRSS2:ERG fusion status. In conclusion, these data identify PTTG1 as a strong and independent prognostic feature in prostate cancer. PTTG1 measurement, either alone or in combination with other biomarkers might be instrumental for determining prostate cancer aggressiveness.

AB - Pituitary tumor-transforming gene 1 (PTTG1) is a regulator of chromosome stability. PTTG1 overexpression had been associated with tumor aggressiveness in several cancer types. To examine its prognostic utility in prostate cancer, a tissue microarray including 12 427 tumors with clinical and molecular data was analyzed by immunohistochemistry. PTTG1 immunostaining was largely absent in normal prostate epithelial cells. In cancers, staining was considered weak in 5.4%, moderate in 5.6% and strong in 0.8%. Strong staining was linked to advanced pT stage, high classical and quantitative Gleason grade, high Ki67-labeling index (all P < 0.0001) and lymph node metastasis (P = 0.0083). The prognostic impact of PTTG1 expression was independent of established preoperative and postoperative prognostic features. Comparison with molecular features revealed that PTTG1 upregulation was associated with nine of 12 common genomic deletions (P < 0.05), p53 alterations and high androgen receptor levels (P < 0.001 each), but was unrelated to the TMPRSS2:ERG fusion status. In conclusion, these data identify PTTG1 as a strong and independent prognostic feature in prostate cancer. PTTG1 measurement, either alone or in combination with other biomarkers might be instrumental for determining prostate cancer aggressiveness.

U2 - 10.1111/pin.12938

DO - 10.1111/pin.12938

M3 - SCORING: Journal article

C2 - 32314536

VL - 70

SP - 441

EP - 451

JO - PATHOL INT

JF - PATHOL INT

SN - 1320-5463

IS - 7

ER -